)
Research and Development
Current R&D Areas of Focus in Transplantation
We currently have three active clinical programs focused on addressing major complications following kidney and stem cell transplantation.
Solid Organ Transplantation
| Compound Number | Investigational Indication | Mode of Action | Stage | Trial Name |
|---|---|---|---|---|
| CSL300 | AMR in Kidney transplant recipients | Anti-IL-6 monoclonal antibody | Phase III |
Interleukin 6 blockade Modifying Antibody-mediated Graft Injury and eGFR decline (IMAGINE) - Learn More For any questions about our IMAGINE trial, or suggestions for additional clinical trial sites, please contact us directly James.Lee2@cslbehring.com |
Stem Cell Transplantation
| Compound Number | Investigational Indication | Mode of Action | Stage | Trial Name |
|---|---|---|---|---|
| CSL964 | GvHD Prevention | Alpha-1 Antitrypsin | Phase II/III |
The Safety and Efficacy of Alpha-1 Antitrypsin for the Prevention of Graft-Versus-Host-Disease in Patients Receiving Hematopoeitic Cell Transplant (MODULAATE) - Learn More For any questions about our MODULAATE trial, or suggestions for additional clinical trial sites, please contact us directly at Michael.Giordani@cslbehring.com |
| CSL964 | GvHD Treatment (collaboration with BMT CTN) | Alpha-1 Antitrypsin | Phase III |
Treatment of GVHD in Hematopoietic Stem Cell Transplant Recipients Using AAT Plus Corticosteroids Compared with Corticosteroids Alone (BMT CTN 1705) - Learn More For any questions about our MODULAATE trial, or suggestions for additional clinical trial sites, please contact us directly at Michael.Giordani@cslbehring.com |